



































WHERE WE INVESTED, 2018-2019

AB 	BC 	MB 	NB 	NL 	NS 	ON 	QC 	SK 
--	---	---	---	---	--	---	---	---

RESEARCH FUNDING PROFILE

Province	Principal Investigator	Project	Funding Period	Total Amount
	Dr. Elizabeth Tullis St. Michael's Hospital, Toronto <i>Matched Funding program</i>	Cystic Fibrosis Canada Chair in Adult Cystic Fibrosis Research at St. Michael's Hospital, Toronto	2014 – 2018	\$500,001
	Dr. Julie Forman-Kay The Hospital for Sick Children, Toronto	Studying the regulatory (R) region of the CFTR protein and its role in controlling ion balance in the cell	2016 – 2019	\$373,782
	Dr. Lisa Strug, The Hospital for Sick Children, Toronto	Understanding the genetic epidemiology of cystic fibrosis	2016 – 2019	\$361,713
	Dr. Valerie Waters The Hospital for Sick Children, Toronto	Conducting a randomized controlled trial of prednisone in cystic fibrosis (CF) pulmonary exacerbations (PIPE Study)	2016 – 2019	\$356,419
	Dr. Christine Bear The Hospital for Sick Children, Toronto	Individualizing cystic fibrosis therapy	2016 – 2019	\$320,951
	Dr. Nades Palaniyar The Hospital for Sick Children, Toronto	Improving CF lung disease through pH-mediated correction of immune functions of neutrophils	2016 – 2019	\$318,764
	Dr. Philip Britz-McKibbin McMaster University, Hamilton	Metabolomics for improved screening and prognosis of cystic fibrosis infants: translation of new biomarkers for resolving diagnostic dilemmas	2018 – 2021	\$300,000
	Dr. Jim Hu The Hospital for Sick Children, Toronto	Enhancing the efficiency of CRISPR-mediated gene correction for cystic fibrosis therapy	2018 – 2021	\$300,000
	Dr. Paul Kubes University of Calgary	Understanding the interplay between alveolar macrophages and <i>P. aeruginosa</i> in the cystic fibrosis lung	2018 – 2021	\$300,000
	Dr. Paul Linsdell Dalhousie University, Halifax	Conformational change opening and closing the CFTR channel	2017 – 2020	\$300,000
	Dr. François Malouin University of Sherbrooke	New antibiotic combination for MRSA and <i>Pseudomonas aeruginosa</i> in cystic fibrosis	2018 – 2021	\$300,000
	Dr. David Thomas McGill University, Montreal & Dr. John Hanrahan McGill University, Montreal <i>2018 Cathleen Morrison Research Impact Awardees</i>	Increasing trafficking of F508del-CFTR: a rational approach	2018 – 2021	\$300,000

	Dr. Daniela Rotin The Hospital for Sick Children, Toronto	Use of lung organoids from CF patients to analyze response to ENaC inhibitors	2018 – 2021	\$299,984
	Dr. Michael Parkins University of Calgary	A comprehensive longitudinal cohort study of infection transmission in cystic fibrosis	2017 – 2020	\$299,982
	Dr. Keith Poole Queen's University, Kingston	Identification and targeting of CF lung-driven antimicrobial resistance in <i>P. aeruginosa</i>	2018 – 2021	\$299,955
	Dr. Charles Deber The Hospital for Sick Children, Toronto	Molecular basis of CF-causing mutations in CFTR	2017 – 2020	\$298,626
	Dr. Rees Kassen University of Ottawa	Evolutionary genetics of chronic infection by <i>Pseudomonas aeruginosa</i> in the cystic fibrosis lung	2017 – 2020	\$297,895
	Dr. David Heinrichs University of Western Ontario, London & Dr. Ronald Flannagan University of Western Ontario, London	Subversion strategies of MRSA in the macrophage	2017 – 2020	\$297,600
	Dr. Gergely Lukacs McGill University, Montreal	Understanding the architecture of misfolded proteins to design structure-based therapies	2016 – 2019	\$293,646
	Dr. Robert Young Simon Fraser University, Burnaby	Defining the molecular interactions and mapping the binding sites of CFTR "corrector" and "potentiator" drugs	2016 – 2019	\$292,161
	Dr. Bradley Quon Centre for Heart Lung Innovation, Vancouver	PIPE-CF Biomarker Study	2017 – 2020	\$291,579
	Dr. Justin Nodwell University of Toronto & Dr. Marie Elliot McMaster University, Hamilton	Therapeutics for CF Pathogens	2017 – 2020	\$289,128
	Dr. Juan Janowski University of Saskatchewan, Saskatoon <i>2018 Senior Scientist Awardee</i>	CF airways fail to clear inhaled pathogens due to abnormal submucosal glands function and hyperactive Na ⁺ reabsorption	2018 – 2021	\$287,771
	Dr. Michael Surette McMaster University, Hamilton	Microbiology of pulmonary exacerbations	2017 – 2020	\$285,000
	Dr. Dao Nguyen McGill University, Montreal	Understanding host-pathogen interactions to improve eradication of initial <i>Pseudomonas aeruginosa</i> infections in CF	2018 – 2021	\$284,691
	Dr. Yossef Av-Gay University of British Columbia, Vancouver	Targeting Intracellular and biofilm associated <i>Mycobacterium abscessus</i> for drug discovery	2017 – 2020	\$279,050
	Dr. Donald Sheppard McGill University, Montreal	Development of therapeutic agents for <i>Pseudomonas</i> and <i>Aspergillus</i> lung disease in cystic fibrosis	2018 – 2021	\$273,834
	Dr. Robert Hancock University of British Columbia, Vancouver	Understanding antibiotic-resistance and developing new therapies against <i>P. aeruginosa</i>	2016 – 2019	\$272,412
	Dr. Basil Petrof McGill University, Montreal	Addressing muscle wasting in cystic fibrosis	2017 – 2020	\$270,468

	Dr. Manish Sadarangani, Dr. David Speert, Dr. Mark Chilvers, and Dr. James Zlosnik University of British Columbia, Vancouver	Canadian <i>Burkholderia cepacia</i> complex Research and Referral Repository (CBCCRRT)	2017 - 2020	\$270,000
	Dr. Michael Murphy The University of British Columbia, Vancouver	Developing novel, target-specific therapeutics for the treatment of <i>Burkholderia cepacia</i> complex infections	2016 - 2019	\$268,098
	Dr. Simon Rousseau McGill University, Montreal	Unravelling the complexity of IL-6 signaling in CF lung disease	2016 - 2019	\$260,118
	Dr. Marcel Behr McGill University, Montreal <i>2018 Robbie Awardee</i>	Non-tuberculous mycobacteria in CF - new chemistries for old targets	2018 - 2021	\$259,700
	Dr. Felix Ratjen The Hospital for Sick Children, Toronto	Evaluating LCI to monitor treatment response for pulmonary exacerbations	2016 - 2019	\$257,264
	Dr. Ryszard Grygorczyk University of Montreal	Understanding the regulation of mucin release and rheology in cystic fibrosis	2016 - 2019	\$213,231
	Dr. Stephen Juvet University Health Network, Toronto <i>2018 Marsha Morton Early Career Investigator Award</i>	Control of the early-post-transplant immunological milieu to prevent lung allograft rejection	2018 - 2020	\$200,000
	Dr. Tanja Gonska The Hospital for Sick Children, Toronto	Interrogation of the prevalence of intestinal inflammation in CF patients and its correlation to abdominal pain	2018 - 2020	\$198,189
	Dr. Rémi Rabasa-Lhoret IRCM, Montreal	Studying the effect of soluble fiber to reduce post-prandial glycemic excursion in adults with CF	2016 - 2019	\$197,666
	Dr. Prashen Chelikani University of Manitoba, Winnipeg	Role of chemosensory bitter taste receptors (T2Rs) in cystic fibrosis	2017 - 2019	\$196,000
	Dr. Dao Nguyen McGill University, Montreal <i>Scholarship Award</i>	Airway epithelial cell inflammatory response to <i>P. aeruginosa</i> clinical isolates and biofilms	2016 - 2018	\$120,000
	Dr. John Hanrahan McGill University, Montreal	Primary Airway Cell Biobank	2017 - 2019	\$112,500
	Dr. John Hanrahan McGill University, Montreal & Dr. Janet Rossant The Hospital for Sick Children, Toronto <i>CIHR partnership</i>	Induced pluripotent stem cells for identification of novel drug combinations targeting cystic fibrosis lung and liver disease	2016 - 2019	\$105,000
	Dr. Lori West University of Alberta, Edmonton <i>CIHR partnership</i>	The Canadian National Transplant Research Program: Increasing donation and improving transplantation outcomes	2018 - 2021	\$60,000
	Dr. Stuart Elborn, Dr. Valerie Waters, Dr. Patrick Flume, Dr. Scott Bell	International Working Group on Antimicrobial Resistance in Cystic Fibrosis	2017 - 2019	\$10,000